ARCA biopharma Statistics
Total Valuation
ARCA biopharma has a market cap or net worth of $47.87 million. The enterprise value is $11.25 million.
Market Cap | 47.87M |
Enterprise Value | 11.25M |
Important Dates
The last earnings date was Thursday, April 25, 2024, after market close.
Earnings Date | Apr 25, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
ARCA biopharma has 14.51 million shares outstanding. The number of shares has increased by 0.63% in one year.
Shares Outstanding | 14.51M |
Shares Change (YoY) | +0.63% |
Shares Change (QoQ) | +0.47% |
Owned by Insiders (%) | 1.29% |
Owned by Institutions (%) | 75.06% |
Float | 4.93M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.34 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.19, with zero debt.
Current Ratio | 23.19 |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -16.10% and return on invested capital (ROIC) is -22.72%.
Return on Equity (ROE) | -16.10% |
Return on Assets (ROA) | -15.50% |
Return on Capital (ROIC) | -22.72% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.50M |
Employee Count | 4 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +57.82% in the last 52 weeks. The beta is 0.88, so ARCA biopharma's price volatility has been lower than the market average.
Beta (1Y) | 0.88 |
52-Week Price Change | +57.82% |
50-Day Moving Average | 2.79 |
200-Day Moving Average | 2.08 |
Relative Strength Index (RSI) | 51.42 |
Average Volume (30 Days) | 1,470,772 |
Short Selling Information
The latest short interest is 4.10 million, so 28.29% of the outstanding shares have been sold short.
Short Interest | 4.10M |
Short Previous Month | 5.66M |
Short % of Shares Out | 28.29% |
Short % of Float | 83.29% |
Short Ratio (days to cover) | 1.02 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -7.98M |
Pretax Income | -6.00M |
Net Income | -6.00M |
EBITDA | -5.90M |
EBIT | -6.00M |
Earnings Per Share (EPS) | -$0.42 |
Balance Sheet
The company has $35.90 million in cash and no debt, giving a net cash position of $35.90 million or $2.47 per share.
Cash & Cash Equivalents | 35.90M |
Total Debt | n/a |
Net Cash | 35.90M |
Net Cash Per Share | $2.47 |
Equity / Book Value | 35.13M |
Book Value Per Share | 2.42 |
Working Capital | 35.09M |
Cash Flow
Operating Cash Flow | -4.95M |
Capital Expenditures | n/a |
Free Cash Flow | -4.95M |
FCF Per Share | -$0.34 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
ARCA biopharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | 1 |
Payout Ratio | n/a |
Buyback Yield | -0.63% |
Shareholder Yield | -0.63% |
Earnings Yield | -12.73% |
FCF Yield | -10.49% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on April 4, 2019. It was a reverse split with a ratio of 1:18.
Last Split Date | Apr 4, 2019 |
Split Type | Reverse |
Split Ratio | 1:18 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |